Publications

Skip to content

Real-world evidence

New and Noteworthy

One Standard, Many Markets: What FDA, EMA, and PMDA Actually Agree On

Real-world evidence
Regulatory

ASCO 2026: Translating oncology innovation into real-world impact
From innovation to strategic insight: making sense of rapid advances in bladder cancer care
- Real-world evidence
- Urothelial cell carcinoma
The real-world perspective: Why global RWE matters in modern oncology

All the latest

Topics

Data management

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Post marketing requirements

Prospective study

Regulatory

Treatment patterns

Trial design

Unmet need

Content type

Article

Case study

Event recap

Podcast

Publications

Video

Webinar

Showing 9 of 0 results

One Standard, Many Markets: What FDA, EMA, and PMDA Actually Agree On
- Real-world evidence
- Regulatory
The new frontier of academic research
- Real-world evidence
- Event recap
A conversation with Dr. Ronac Mamtani on the evidence that moves oncology forward
- Real-world evidence
- Event recap
ASCO 2026: Translating oncology innovation into real-world impact
Rewriting the real-world evidence playbook for clinical development
ISPOR 2026 reflections: AI, access, and the evolving role of RWE in oncology
From innovation to strategic insight: making sense of rapid advances in bladder cancer care
- Real-world evidence
- Urothelial cell carcinoma
Unlocking the next level of RWD: Flatiron’s Scientific Vision
The real-world perspective: Why global RWE matters in modern oncology

Real answers to guide oncology’s highest-stakes decisions.

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2026